MA47370A - Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines - Google Patents

Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines

Info

Publication number
MA47370A
MA47370A MA047370A MA47370A MA47370A MA 47370 A MA47370 A MA 47370A MA 047370 A MA047370 A MA 047370A MA 47370 A MA47370 A MA 47370A MA 47370 A MA47370 A MA 47370A
Authority
MA
Morocco
Prior art keywords
heteraryl
modulators
bis
derivatives
protein aggregation
Prior art date
Application number
MA047370A
Other languages
English (en)
Inventor
Adrian Hall
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA47370A publication Critical patent/MA47370A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047370A 2017-01-26 2018-01-23 Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines MA47370A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17153214 2017-01-26

Publications (1)

Publication Number Publication Date
MA47370A true MA47370A (fr) 2021-03-24

Family

ID=57906527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047370A MA47370A (fr) 2017-01-26 2018-01-23 Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines

Country Status (16)

Country Link
US (1) US10913735B2 (fr)
EP (1) EP3573982B1 (fr)
JP (1) JP7100043B2 (fr)
KR (1) KR20190111080A (fr)
CN (1) CN110198938B (fr)
AU (1) AU2018212436A1 (fr)
BR (1) BR112019011932A2 (fr)
CL (1) CL2019001752A1 (fr)
CO (1) CO2019007835A2 (fr)
EA (1) EA201991756A1 (fr)
ES (1) ES2882285T3 (fr)
IL (1) IL267994A (fr)
MA (1) MA47370A (fr)
MX (1) MX2019007053A (fr)
RU (1) RU2019126170A (fr)
WO (1) WO2018138086A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009347A0 (en) 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
EP3328379B1 (fr) 2015-07-29 2021-07-28 UCB Biopharma SRL Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
CN110198938B (zh) * 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
KR20190112031A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
WO2023125376A1 (fr) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 Composé hétéroarylamide bicyclique fusionné utile en tant qu'inhibiteur de l'agrégation de protéines
WO2024233951A1 (fr) * 2023-05-10 2024-11-14 The Trustees Of The University Of Pennsylvania Composés hétérocycliques pour l'imagerie d'alpha-synucléine agrégée dans les synucléinopathies
WO2025002040A1 (fr) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 Forme cristalline ou sel d'un composé hétéroaryle bicyclique amide, son procédé de préparation et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
KR20120112548A (ko) 2009-12-16 2012-10-11 뉴로포레 테라피스, 인코포레이티드 시누클레인 병을 치료하는데 적합한 화합물
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (fr) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Procédés et composés pouvant être utilisés pour traiter les maladies neurodégénératives
MX2014011615A (es) 2012-03-28 2015-01-19 Neuropore Therapies Inc Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina.
CN104703604A (zh) 2012-07-16 2015-06-10 神经孔疗法股份有限公司 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物
AP2016009347A0 (en) 2014-01-29 2016-07-31 Neuropore Therapies Inc Heteroarly amides as inhibitors of protein aggregation
EP3328379B1 (fr) * 2015-07-29 2021-07-28 UCB Biopharma SRL Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
EA201991755A1 (ru) * 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
CN110198938B (zh) * 2017-01-26 2023-03-14 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的双-杂芳基衍生物
KR20190112031A (ko) * 2017-01-26 2019-10-02 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체

Also Published As

Publication number Publication date
AU2018212436A1 (en) 2019-07-25
ES2882285T3 (es) 2021-12-01
MX2019007053A (es) 2019-08-29
CN110198938A (zh) 2019-09-03
EA201991756A1 (ru) 2020-01-23
RU2019126170A (ru) 2021-02-26
EP3573982A1 (fr) 2019-12-04
CO2019007835A2 (es) 2019-07-31
US10913735B2 (en) 2021-02-09
CA3048947A1 (fr) 2018-08-02
BR112019011932A2 (pt) 2019-10-29
US20190367502A1 (en) 2019-12-05
IL267994A (en) 2019-09-26
JP7100043B2 (ja) 2022-07-12
WO2018138086A1 (fr) 2018-08-02
EP3573982B1 (fr) 2021-06-16
CL2019001752A1 (es) 2019-11-22
CN110198938B (zh) 2023-03-14
JP2020505372A (ja) 2020-02-20
KR20190111080A (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
EP3328379A4 (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
FR24C1039I2 (fr) Compositions modulant l'expression de sod-1
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
EP3353328A4 (fr) Modulateurs de l'expression de kras
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA49055A (fr) Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
EP3554506A4 (fr) Dérivés d'hétéroaryle bycyclique en tant que potentialisateurs du cftr
PL3440076T3 (pl) Heterocykliczne amidy przydatne jako modulatory białek
EP3356356A4 (fr) Composés utiles en tant que modulateurs de trpm8
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA42810A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue